Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a share repurchase transaction executed on May 4, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,300,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,455 pence per share; lowest price paid was 1,425 pence per share.
- Treasury Holdings (Settled): 519,497,927 shares (9.34% of total issued share capital).
- Treasury Holdings (Including Unsettled): 523,597,927 shares (10.38% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,044,558,897 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,300,000 shares for Treasury. Consequently, the percentage of shares held in Treasury increased to 10.38% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,044,558,897) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the total Treasury share count (523,597,927) to assess the impact on voting rights.
- Review the price paid (1,425–1,455 pence) against market prices on May 4, 2012.